Skip to Main Content
CKG
Home
Home
Home
TKG
Author details
Breadcrumb
Author Details
Full Name
Shane White
Affiliation
Olivia Newton-John Cancer Wellness and Research Centre
ORCID
Career Start Year
2000
Papers
32
H Index
18
Expertise
CM4AI Collaborator
PMID
Paper Title
Journal Title
Published Year
36271726
Effects of aromatase inhibitor therapy on visceral adipose tissue area and cardiometabolic health in postmenopausal women with early and locally advanced breast cancer.
Clin Endocrinol (Oxf)
2023
36271726
Effects of aromatase inhibitor therapy on visceral adipose tissue area and cardiometabolic health in postmenopausal women with early and locally advanced breast cancer.
Clin Endocrinol (Oxf)
2023
37522858
Effects of aromatase inhibitor therapy on adiposity and cardiometabolic health in postmenopausal women: a controlled cohort extension study.
Endocr Connect
2023
37522858
Effects of aromatase inhibitor therapy on adiposity and cardiometabolic health in postmenopausal women: a controlled cohort extension study.
Endocr Connect
2023
35677588
Including migrant oncology patients in research: A multisite pilot randomised controlled trial testing consultation audio-recordings and question prompt lists.
Contemp Clin Trials Commun
2022
35677588
Including migrant oncology patients in research: A multisite pilot randomised controlled trial testing consultation audio-recordings and question prompt lists.
Contemp Clin Trials Commun
2022
32110415
Durvalumab induced sarcoid-like pulmonary lymphadenopathy.
Respirol Case Rep
2020
32110415
Durvalumab induced sarcoid-like pulmonary lymphadenopathy.
Respirol Case Rep
2020
28762618
Exploring disparities in receipt of adjuvant chemotherapy in culturally and linguistically diverse groups: an Australian centre's experience.
Intern Med J
2018
28762618
Exploring disparities in receipt of adjuvant chemotherapy in culturally and linguistically diverse groups: an Australian centre's experience.
Intern Med J
2018
29893041
Culturally and linguistically diverse oncology patients' perspectives of consultation audio-recordings and question prompt lists.
Psychooncology
2018
30107043
The benefits of adding metformin to tamoxifen to protect the endometrium-A randomized placebo-controlled trial.
Clin Endocrinol (Oxf)
2018
30239842
Intravaginal Testosterone Improves Sexual Satisfaction and Vaginal Symptoms Associated With Aromatase Inhibitors.
J Clin Endocrinol Metab
2018
30107043
The benefits of adding metformin to tamoxifen to protect the endometrium-A randomized placebo-controlled trial.
Clin Endocrinol (Oxf)
2018
29893041
Culturally and linguistically diverse oncology patients' perspectives of consultation audio-recordings and question prompt lists.
Psychooncology
2018
30239842
Intravaginal Testosterone Improves Sexual Satisfaction and Vaginal Symptoms Associated With Aromatase Inhibitors.
J Clin Endocrinol Metab
2018
26993131
A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors.
Breast Cancer Res Treat
2016
26993131
A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors.
Breast Cancer Res Treat
2016
24575793
Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC.
Asia Pac J Clin Oncol
2015
24575793
Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC.
Asia Pac J Clin Oncol
2015
24365050
Third-line chemotherapy in small-cell lung cancer: an international analysis.
Clin Lung Cancer
2014
24365050
Third-line chemotherapy in small-cell lung cancer: an international analysis.
Clin Lung Cancer
2014
24995129
A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer.
J Immunother Cancer
2014
24995129
A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer.
J Immunother Cancer
2014
23935846
The role of Cancer-Testis antigens as predictive and prognostic markers in non-small cell lung cancer.
PLoS One
2013
24403265
Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non-small cell lung cancer.
Cancer Med
2013
23935846
The role of Cancer-Testis antigens as predictive and prognostic markers in non-small cell lung cancer.
PLoS One
2013
24403265
Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non-small cell lung cancer.
Cancer Med
2013
22897880
Syndrome of inappropriate anti-diuretic hormone secretion secondary to carboplatin after docetaxel-carboplatin-trastuzumab combination for early stage HER-2 positive breast cancer.
Asia Pac J Clin Oncol
2012
22937937
Paraneoplastic leukocytoclastic vasculitis as an initial presentation of malignant pleural mesothelioma: a case report.
J Med Case Rep
2012
22872523
Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer.
Breast Cancer Res Treat
2012
22897880
Syndrome of inappropriate anti-diuretic hormone secretion secondary to carboplatin after docetaxel-carboplatin-trastuzumab combination for early stage HER-2 positive breast cancer.
Asia Pac J Clin Oncol
2012
22937937
Paraneoplastic leukocytoclastic vasculitis as an initial presentation of malignant pleural mesothelioma: a case report.
J Med Case Rep
2012
22872523
Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer.
Breast Cancer Res Treat
2012
21574834
Inflammatory breast cancer and secondary Pure Red Cell Aplasia.
Acta Oncol
2011
21574834
Inflammatory breast cancer and secondary Pure Red Cell Aplasia.
Acta Oncol
2011
19675093
The strength of female sex as a prognostic factor in small-cell lung cancer: a pooled analysis of chemotherapy trials from the Manchester Lung Group and Medical Research Council Clinical Trials Unit.
Ann Oncol
2010
19675093
The strength of female sex as a prognostic factor in small-cell lung cancer: a pooled analysis of chemotherapy trials from the Manchester Lung Group and Medical Research Council Clinical Trials Unit.
Ann Oncol
2010
19921339
High impact of 18F-FDG-PET on management and prognostic stratification of newly diagnosed small cell lung cancer.
Mol Imaging Biol
2010
19921339
High impact of 18F-FDG-PET on management and prognostic stratification of newly diagnosed small cell lung cancer.
Mol Imaging Biol
2010
18979266
Motesanib diphosphate (AMG 706), an oral angiogenesis inhibitor, demonstrates clinical efficacy in advanced thymoma.
Acta Oncol
2009
18979266
Motesanib diphosphate (AMG 706), an oral angiogenesis inhibitor, demonstrates clinical efficacy in advanced thymoma.
Acta Oncol
2009
17681104
Modification of leucovorin dose within a simplified FOLFOX regimen improves tolerability without compromising efficacy.
Clin Colorectal Cancer
2007
17681104
Modification of leucovorin dose within a simplified FOLFOX regimen improves tolerability without compromising efficacy.
Clin Colorectal Cancer
2007
16467101
Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma.
Clin Cancer Res
2006
16467101
Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma.
Clin Cancer Res
2006
16969346
Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer.
Br J Cancer
2006
16945171
Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity.
Clin Colorectal Cancer
2006
16969346
Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer.
Br J Cancer
2006
16945171
Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity.
Clin Colorectal Cancer
2006
1 - 50 of 64
Column Actions
Search
Recommended Authors
Philip E Lammers
Baptist Cancer Center
Career Start Year
2013
Number of shared co-authors
1
Jyoti Malhotra
Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School
Career Start Year
2012
Number of shared co-authors
1
Sara Kuruvilla
Schulich School of Medicine and Dentistry, Western University
Career Start Year
2010
Number of shared co-authors
4
Saiama N Waqar
Siteman Cancer Center, Washington University School of Medicine
Career Start Year
2009
Number of shared co-authors
0
Gideon M Blumenthal
Oncology Center of Excellence
Career Start Year
2008
Number of shared co-authors
1
Shubham Pant
The University of Texas MD Anderson Cancer Center
Career Start Year
2005
Number of shared co-authors
0
Edward B Garon
David Geffen School of Medicine, University of California Los Angeles
Career Start Year
2005
Number of shared co-authors
2
Matthew A Gubens
University of California san francisco
Career Start Year
2003
Number of shared co-authors
0
Daniel Morgensztern
Washington University School of Medicine
Career Start Year
2000
Number of shared co-authors
1
Sunil Sharma
Brody School of Medicine, East Carolina University
Career Start Year
1997
Number of shared co-authors
2
Primo N Lara
University of California Davis Comprehensive Cancer Center
Career Start Year
1996
Number of shared co-authors
3
Lillian L Siu
Princess Margaret Cancer Centre, University Ave
Career Start Year
1995
Number of shared co-authors
4
Stefan Sleijfer
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Career Start Year
1994
Number of shared co-authors
1
Vincent A Miller
Injury Prevention Research Center, University of North Carolina
Career Start Year
1994
Number of shared co-authors
2
Jonathan W Goldman
David Geffen School of Medicine at university of california los angeles
Career Start Year
1991
Number of shared co-authors
3
Dean A Fennell
University of Leicester
Career Start Year
1990
Number of shared co-authors
4
Suresh Nair
Lehigh Valley Topper Cancer Institute
Career Start Year
1990
Number of shared co-authors
1
Emile E Voest
The Netherlands Cancer Institute
Career Start Year
1989
Number of shared co-authors
1
Charles M Rudin
Memorial Sloan Kettering Cancer Center
Career Start Year
1989
Number of shared co-authors
7
Jose A Lopez-Martin
Hospital Universitario 12 de Octubre
Career Start Year
1988
Number of shared co-authors
0
Chris Twelves
Leeds Teaching Hospitals NHS Trust, University of Leeds
Career Start Year
1986
Number of shared co-authors
2
David C Smith
Rogel Comprehensive Cancer Center, University of Michigan ann arbor
Career Start Year
1985
Number of shared co-authors
0
Seth M Steinberg
Center for Cancer Research, National Cancer Institute
Career Start Year
1984
Number of shared co-authors
1
Roy S Herbst
Yale School of Medicine
Career Start Year
1984
Number of shared co-authors
5
Helen J Ross
Mayo Clinic
Career Start Year
1982
Number of shared co-authors
3
Ramaswamy Govindan
Siteman Cancer Center, Washington University School of Medicine
Career Start Year
1981
Number of shared co-authors
7
Giuseppe Giaccone
Meyer Cancer Center
Career Start Year
1981
Number of shared co-authors
5
Antonio Jimeno
University of Colorado School of Medicine
Career Start Year
1974
Number of shared co-authors
0
James H Doroshow
National Cancer Institute, National Institutes of Health
Career Start Year
1974
Number of shared co-authors
1
Ronald de Wit
Erasmus MC Cancer Institute
Career Start Year
1972
Number of shared co-authors
1
row(s) 1 - 30 of 30
Collaborators
Paul Mitchell
Olivia Newton-John Cancer Research Institute
Co-authored papers
9
Arun A Azad
Peter MacCallum Cancer Centre
Co-authored papers
3
Thomas John
Peter MacCallum Cancer Centre
Co-authored papers
3
Susan R Davis
School of Public Health and Preventive Medicine, Monash University
Co-authored papers
2
Fiona Jane
Co-authored papers
2
Robin J Bell
School of Public Health and Preventive Medicine, Monash University
Co-authored papers
2
Allan Zimet
Epworth Hospital
Co-authored papers
2
Mun Sem Liew
The University of Melbourne
Co-authored papers
2
Susan R Davis
Co-authored papers
2
Paul C Boutros
University of California los angeles
Co-authored papers
2
Philippe Lambin
Maastricht University
Co-authored papers
2
Sam Harris
Co-authored papers
2
Penelope J Robinson
School of Public Health and Preventive Medicine, Monash University
Co-authored papers
2
Maud H W Starmans
Ontario Institute for Cancer Research
Co-authored papers
2
Paul Wheatley-Price
The Ottawa Hospital Research Institute
Co-authored papers
2
Prudence A Russell
St Vincent's Hospital
Co-authored papers
1
Cheryl Ho
University of British Columbia
Co-authored papers
1
Marzena Walkiewicz
Olivia Newton-John Cancer Research Institute
Co-authored papers
1
Joseph Sia
Peter MacCallum Cancer Centre, University of Melbourne
Co-authored papers
1
Ali Tafreshi
University of Wollongong
Co-authored papers
1
Andrew Edwards
Co-authored papers
1
L J McNeilage
Co-authored papers
1
Mitchell Chipman
Co-authored papers
1
Siddhartha Deb
Olivia Newton-John Cancer Research Institute
Co-authored papers
1
Stephen Barnett
Royal Melbourne Hospital
Co-authored papers
1
Ming-Sound Tsao
University Health Network, University of Toronto
Co-authored papers
1
Sofie Piessens
Co-authored papers
1
Clement Ma
Co-authored papers
1
Kristy A Brown
Co-authored papers
1
Jonathan Cebon
Australia Olivia Newton-John Cancer Research Institute, La Trobe University
Co-authored papers
1
1 - 30